JP2006528621A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528621A5
JP2006528621A5 JP2006520928A JP2006520928A JP2006528621A5 JP 2006528621 A5 JP2006528621 A5 JP 2006528621A5 JP 2006520928 A JP2006520928 A JP 2006520928A JP 2006520928 A JP2006520928 A JP 2006520928A JP 2006528621 A5 JP2006528621 A5 JP 2006528621A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
nhch
cycloalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006520928A
Other languages
English (en)
Japanese (ja)
Other versions
JP4896717B2 (ja
JP2006528621A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/002355 external-priority patent/WO2005009975A2/en
Publication of JP2006528621A publication Critical patent/JP2006528621A/ja
Publication of JP2006528621A5 publication Critical patent/JP2006528621A5/ja
Application granted granted Critical
Publication of JP4896717B2 publication Critical patent/JP4896717B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006520928A 2003-07-24 2004-07-12 N−メチル−置換ベンゾアミダゾール Expired - Fee Related JP4896717B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49001203P 2003-07-24 2003-07-24
US60/490,012 2003-07-24
PCT/IB2004/002355 WO2005009975A2 (en) 2003-07-24 2004-07-12 Benzimidazole derivatives as mek inhibitors

Publications (3)

Publication Number Publication Date
JP2006528621A JP2006528621A (ja) 2006-12-21
JP2006528621A5 true JP2006528621A5 (https=) 2007-08-30
JP4896717B2 JP4896717B2 (ja) 2012-03-14

Family

ID=34102957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006520928A Expired - Fee Related JP4896717B2 (ja) 2003-07-24 2004-07-12 N−メチル−置換ベンゾアミダゾール

Country Status (10)

Country Link
US (1) US7160915B2 (https=)
EP (1) EP1651214B1 (https=)
JP (1) JP4896717B2 (https=)
AT (1) ATE442847T1 (https=)
BR (1) BRPI0412851A (https=)
CA (1) CA2532067C (https=)
DE (1) DE602004023207D1 (https=)
ES (1) ES2331246T3 (https=)
MX (1) MXPA06000921A (https=)
WO (1) WO2005009975A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
CA2612419C (en) * 2005-06-23 2017-06-13 Array Biopharma Inc. Process for preparing benzimidazole compounds
AU2006262375A1 (en) * 2005-06-23 2007-01-04 Array Biopharma Inc. SNAr process for preparing benzimidazole compounds
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
ATE551336T1 (de) * 2007-08-16 2012-04-15 Hoffmann La Roche Substituierte hydantoine
CN101868443A (zh) 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
WO2009037705A2 (en) * 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. Esters of n-phenylanthranilic acid for use in the treatment of cancer and inflammation
ES2456966T3 (es) 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
JP2011506533A (ja) 2007-12-20 2011-03-03 エフ.ホフマン−ラ ロシュ アーゲー Mekキナーゼ阻害剤としての置換ヒダントイン
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
ES2426096T3 (es) * 2008-07-01 2013-10-21 Genentech, Inc. Derivados de isoindolona como inhibidores de la quinasa MEK y métodos de utilización
US8993630B2 (en) 2008-11-10 2015-03-31 Bayer Intellectual Property Gmbh Substituted sulphonamido phenoxybenzamides
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
US20120269803A1 (en) 2009-10-21 2012-10-25 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
EP2491014A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
CN103204825B (zh) 2012-01-17 2015-03-04 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
JP2015527874A (ja) 2012-05-31 2015-09-24 バイエル ファーマ アクチエンゲゼルシャフト 肝細胞癌(hcc)患者の治療の有効な応答を決定するためのバイオマーカー
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
FI3702351T3 (fi) * 2012-10-19 2024-01-24 Array Biopharma Inc MEK-inhibiittorin käsittävä koostumus
CN111518031B (zh) * 2020-05-29 2023-01-17 中国药科大学 一种含有异羟肟酸的化合物及其制备方法、应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
AU5610398A (en) 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
IL125425A (en) 1998-07-20 2008-12-29 Israel State ADPGPPase CONTROL OF STARCH SYNTHESIS IN TOMATOES
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
KR20020012315A (ko) 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Mek 저해제를 사용한 만성 통증의 치료 방법
PL352835A1 (en) * 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
ATE497603T1 (de) 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors

Similar Documents

Publication Publication Date Title
JP2006528621A5 (https=)
JP2006500394A5 (https=)
JP2007517044A5 (https=)
JP2012505871A5 (https=)
JP2007513170A5 (https=)
JP2005510476A5 (https=)
JP2008505120A5 (https=)
JP2005508967A5 (https=)
JP2014530900A5 (https=)
KR930005992A (ko) 루코트리엔 생합성 억제제
JP2001525411A5 (https=)
JP2007504161A5 (https=)
JP2017518959A5 (https=)
CA2679232A1 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
JP2007533741A5 (ja) Bace阻害剤として有用なピロリジン誘導体
JP2006524660A5 (https=)
JP2013509442A5 (https=)
JP2008510828A5 (https=)
JP2017507160A5 (https=)
JP2007517035A5 (https=)
JP2006507355A5 (https=)
JP2013538230A5 (https=)
JP2018536648A5 (https=)
JP2015523980A5 (https=)
JP2010501478A5 (https=)